预约演示

更新于：2026-08-27

ABBV-706

更新于：2026-08-27

概要

概要

基本信息

药物类型

ADC

别名

Humanised IgG1 monoclonal antibody against SEZ6, conjugated to (2S)-2-(2-bromoacetamido)-N-[(2S)-1-({3-[(7S)-7-ethyl-7-hydroxy-8,11-dioxo-7,8,11,13-tetrahydro-2H,10H-[1,3]dioxolo[4,5-g]pyrano[3',4':6,7]indolizino[1,2-b]quinolin-14-yl]bicyclo[1.1.1]pentan-1-yl}amino)-1-oxopropan-2-yl]-3-methylbutanamide、ABBV 706、ABBV706

靶点

SEZ6 x Top I

作用方式

抑制剂

作用机制

SEZ6抑制剂(seizure related 6 homolog inhibitors)、TOP1抑制剂(DNA拓扑异构酶I抑制剂)

治疗领域

肿瘤呼吸系统疾病

在研适应症

小细胞肺癌复发性小细胞肺癌广泛期小细胞肺癌+ [3]

非在研适应症-

原研机构

AbbVie, Inc.

在研机构

AbbVie, Inc.

非在研机构-

权益机构-

最高研发阶段临床3期

首次获批日期-

最高研发阶段(中国)临床3期

特殊审评孤儿药 (美国)、孤儿药 (欧盟)

登录后查看时间轴

结构/序列

使用我们的ADC技术数据为新药研发加速。

或

查看完整样例数据

Sequence Code 161983L

当前序列信息引自: *****

Sequence Code 453185874H

当前序列信息引自: *****

关联

项与 ABBV-706 相关的临床试验

NCT07365241

/ Recruiting临床3期

A Phase 3 Randomized, Open Label, Multicenter Study to Evaluate the Safety and Efficacy of ABBV-706 Versus Standard of Care in Subjects With Relapsed/Refractory Small Cell Lung Cancer (SCLC)

Small cell lung cancer (SCLC) is characterized by aggressive and rapid growth and a tendency to develop early spread to distant sites including mediastinal lymph nodes, liver, bones, adrenal glands, and brain. The purpose of this study is to assess safety, tolerability, and change in disease activity of ABBV-706 compared to standard of care (SOC) treatment (topotecan, lurbinectedin, or amrubicin).
ABBV-706 is an investigational drug being developed for the treatment of SCLC. There are two treatment arms in this study. Participants will either receive ABBV-706 or SOC. Approximately 531 adult participants will be enrolled in the study across 175 sites worldwide.
Participants with SCLC will receive intravenous (IV) ABBV-706 or SOC [topotecan (IV or orally), or lubinectedin (IV), or amrubicin (IV)]. The estimated duration of the study is approximately 53 months.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and may require frequent medical assessments, blood tests, questionnaires, and scans.

开始日期2026-07-02

申办/合作机构

AbbVie, Inc.

NCT07155174

/ Recruiting临床2期

A Phase 2 Randomized, Open Label, Multicenter Study to Evaluate the Optimal Dose, Safety, and Efficacy of ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Subjects With Previously Untreated Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Small cell lung cancer (SCLC) is characterized by aggressive and rapid growth and a tendency to develop early spread to distant sites including mediastinal lymph nodes, liver, bones, adrenal glands, and brain. The purpose of this study is to assess safety, dose, change in disease activity of ABBV-706 given with atezolizumab, compared to standard of care (SOC) treatment (etoposide, carboplatin, atezolizumab, and optional lurbinectedin).
ABBV-706 is an investigational drug being developed for the treatment of SCLC. There are multiple treatment arms in this study. Participants will either receive ABBV-706 given with atezolizumab, at 1 of 2 doses, or SOC. Approximately 180 adult participants will be enrolled in the study across sites worldwide.
In the safety lead-in, participants with SCLC will receive intravenous (IV) ABBV-706 in 1 of 2 doses with IV atezolizumab, or IV SOC. In the expansion portion of the study, participants with SCLC will receive IV ABBV-706 in 1 of 2 doses with atezolizumab, or IV SOC, until the optimal dose of ABBV-706 is determined. The estimated duration of the study is up to 69.5 months.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and may require frequent medical assessments, blood tests, questionnaires, and scans.

开始日期2025-11-25

申办/合作机构

AbbVie, Inc.

NCT05599984

/ Active, not recruiting临床1期

A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ABBV-706 as Monotherapy and in Combination With Budigalimab (ABBV-181), Carboplatin, or Cisplatin in Adult Subjects With Advanced Solid Tumors

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess safety, tolerability, pharmacokinetics and preliminary efficacy of ABBV-706 as a monotherapy and in combination with budigalimab, carboplatin, or cisplatin.
ABBV-706 is an investigational drug being developed for the treatment of small cell lung cancer (SCLC), high-grade central nervous system (CNS) tumors and high-grade neuroendocrine carcinomas (NECs). There are multiple treatment arms in this study. Participants will either receive ABBV-706 as a single agent or in combination with budigalimab (another investigational drug), carboplatin or cisplatin at different doses. Approximately 319 adult participants will be enrolled in the study across sites worldwide.
In part 1 (dose escalation), ABBV-706 will be intravenously infused in escalating doses as a monotherapy until the maximum tolerated dose (MTD) is determined in participants with SCLC, high-grade CNS tumors, and high-grade NECs. In part 2, multiple doses will be selected from Part 1 and SCLC participants will be assigned to one of these doses in a randomized fashion to determine the recommended Phase 2 dose. In Part 3a, participants with SCLC or NECs will receive ABBV-706 in combination with budigalimab intravenously every 3 weeks. In Part 3b participants with SCLC or NECs will receive ABBV-706 in combination with either carboplatin or cisplatin intravenously. In Part 4a, participants with CNS tumors will receive ABBV-706 intravenously at a dose determined from Part 1. In Part 4b, participants with NECs will receive ABBV-706 intravenously at a dose selected from Part 1. The estimated duration of the study is up to 4 years.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and may require frequent medical assessments, blood tests, and scans.

开始日期2022-12-05

申办/合作机构

AbbVie, Inc.

100 项与 ABBV-706 相关的临床结果

登录后查看更多信息

100 项与 ABBV-706 相关的转化医学

登录后查看更多信息

100 项与 ABBV-706 相关的专利（医药）

登录后查看更多信息

项与 ABBV-706 相关的文献（医药）

NATURE MEDICINE

SEZ6-targeting antibody−drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial

Article

作者: Ferlini, Cristiano ; Hingorani, Pooja ; Han, Ji-Youn ; Bar, Jair ; Wang, Song ; Choudhury, Noura J ; Kim, Joo-Hang ; Robinson, Randy R ; Dowlati, Afshin ; Chandana, Sreenivasa ; Morgensztern, Daniel ; Munasinghe, Wijith ; Kim, Tae Min ; Rivell, Guillermo ; Chiang, Anne C ; Akerley, Wallace ; Palenski, Tammy ; Paz-Ares, Luis ; Vieito, María ; Kohlhapp, Frederick J ; Byers, Lauren Averett ; Papadopoulos, Kyriakos P ; Kim, Young-Chul ; Meiman, Darius ; Furqan, Muhammad ; Yokouchi, Hiroshi ; Cooper, Alissa J ; Cho, Byoung Chul ; Ahn, Myung-Ju ; Ogunyankin, Oluwadamilola ; Jahchan, Nadine

Abstract:

Seizure-related homolog 6 (SEZ6) is expressed in small cell lung cancer (SCLC) and neuroendocrine neoplasms. In an open label, phase 1 trial, ABBV-706, an antibody−drug conjugate with a SEZ6-directed antibody linked to topoisomerase-1 inhibitor (Top1i), was administered intravenously every 3 weeks (Q3W) to 288 patients with advanced solid tumors; 240 received monotherapy, including 124 with relapsed/refractory (R/R) SCLC. Primary objectives of dose escalation (part 1, advanced solid tumors), dose optimization and expansion (part 2, R/R SCLC only) and dose expansion (part 4, central nervous system tumors and high-grade neuroendocrine neoplasms only) were to evaluate the safety, tolerability, pharmacokinetics (PK), immunogenicity and antitumor activity of ABBV-706 monotherapy and, from parts 1 and 2, to determine the recommended phase 2 dose (RP2D) of ABBV-706 in R/R SCLC. In the monotherapy cohort ( N = 240), the most common treatment-related adverse events (TRAEs) at any grade were anemia (61%) and fatigue (38%). Grade 3 or higher TRAEs occurred in 61% of patients and were dose dependent (39% at 1.8 mg kg −1 and 70% at 2.5 mg kg −1 ). In the R/R SCLC monotherapy cohort ( n = 124), any-grade and grade 3 or higher TRAEs occurred in 93% and 61% of patients, respectively. ABBV-706 demonstrated promising preliminary efficacy in patients with R/R SCLC, with an objective response rate (ORR) of 52% (65/124). In patients with R/R SCLC receiving monotherapy in dose optimization and expansion part 2, ORR was similar between 1.8 mg kg −1 and 2.5 mg kg −1 doses (56% (23/41) and 59% (23/39), respectively), with a duration of response that was highest at the 1.8 mg kg −1 dose and with most patients achieving rapid and durable tumor reduction. Although exploratory, long-term efficacy measures were an important consideration in the RP2D determination, and in R/R SCLC monotherapy, overall survival (OS) was highest at the 1.8 mg kg −1 dose, with a median OS of 12.4 months. Based on the totality of available data, including, but not limited to, safety, preliminary efficacy measures and PK, 1.8 mg kg −1 Q3W was confirmed as the optimal RP2D for patients with R/R SCLC. ClinicalTrials.gov: NCT05599984 .

Cancers

Decoding Small Cell Lung Cancer: Molecular Subtypes, Surface Antigens, and the Target-Modality Problem

Review

作者: Richani Meinhardt, Fedor Wadi ; Rosas, Daniel ; Hussein, Atif ; Akgun, Salih ; Zambrano Iglesias, Mijail I. ; Padron Cubillan, Ines C. ; Raez, Luis E.

Small cell lung cancer (SCLC) has historically been treated as a single, uniformly aggressive disease defined by neuroendocrine differentiation, near-universal loss of TP53 and RB1, and the absence of classical druggable oncogene addictions. Two converging lines of evidence are now reshaping that view. First, transcriptomic profiling has resolved SCLC into molecular subtypes—SCLC-A (ASCL1-driven), SCLC-N (NEUROD1-driven), SCLC-P (POU2F3-driven), and SCLC-I (inflamed)—with distinct immune microenvironments, surface-antigen expression patterns, and emerging therapeutic vulnerabilities, although intratumoral heterogeneity and phenotypic plasticity complicate clean subtype assignment. Second, the development of delta-like ligand 3 (DLL3)-directed therapies provides a natural experiment: the same validated surface antigen failed as an antibody–drug conjugate (rovalpituzumab tesirine, three negative randomized trials) yet succeeded as a bispecific T-cell engager (tarlatamab, which received FDA accelerated approval in 2024 and subsequent traditional FDA approval in 2025 following positive confirmatory phase 3 data). In this review, we integrate the current first-line standard of care—chemoimmunotherapy with atezolizumab- or durvalumab-based regimens followed by maintenance intensification with lurbinectedin–atezolizumab (IMforte)—with the molecular framework of subtypes and biomarkers, and we use DLL3 as a case study to propose that delivery modality is an important determinant of therapeutic success in SCLC and should be considered alongside target biology and tumor heterogeneity. Rapid proliferation, antigen heterogeneity, subtype plasticity, and a relatively less immunogenic microenvironment systematically penalize modalities dependent on payload accumulation and cell-cycle progression and reward modalities that recruit catalytic, cell-cycle-independent cytotoxic effectors. The emerging B7-H3 and SEZ6 programs—including ifinatamab deruxtecan and ABBV-706—are the next test of this framework. We discuss implications for biomarker development, trial design, and the operational challenges of subtype-guided precision oncology in a disease where tissue is scarce and biology shifts under therapy.

117

项与 ABBV-706 相关的新闻（医药）

2026-08-26

·十亿分子

WCLC 2026 前瞻：双抗、ADC 与小分子重塑肺癌治疗格局

每年一届的世界肺癌大会（WCLC）都是全球肺癌药物研发的「风向标」。今年 9/12 日 WCLC 的前瞻摘要已经发布，本公众号初步梳理出了 420 条摘要，其中 169 条披露了临床疗效或安全性数据。阅读之后，给人的初步印象：双抗/多抗与 ADC 正从「概念验证」全面走向「改写标准治疗」，小分子则在罕见靶点与耐药场景继续「精雕细琢」。以下是看完摘要后的整体印象，后续本公众号将进一步跟进感兴趣的研发药物精细分析。一、双抗/三抗：免疫治疗的「下半场」，比的是谁先拿到 OS 免疫检查点抑制剂的白热化竞争，PD-1×VEGF 双特异性抗体扎堆出现，三抗临床数据也进一步增加。本届双抗的两大值得高度关注的方向无疑是：同时靶向免疫+血管的「1+1」组合，以及三靶点免疫协同临床数据。 ① PD-1×VEGF 双抗成为「抗血管+免疫」的集大成者。ivonescimab（PD-1×VEGF）在 HARMONi 全球 III 期研究中，针对三代 EGFR-TKI 耐药后的 EGFR 突变晚期 NSCLC：联合组中位 OS 16.8 个月 vs 安慰剂+化疗 14.0 个月，HR 0.76（95%CI 0.61–0.95），nominal P=0.0151，是首个在该场景带来生存获益的双抗；≥3 级 TRAE 51.4% vs 43.6%，安全性整体可控。国产 RC148（PD-1×VEGF）一线治疗鳞状 NSCLC：10 mg/kg 组 ORR 达 90.0%，其中 PD-L1 阴性亚组 93.3%，mPFS 10.8 个月，差异化卡位 PD-L1 阴性人群。 ② EGFR 突变「双抗+TKI」成主流打法。amivantamab（EGFR×c-MET）联合 lazertinib（EGFRi）在 AMIGO-1 研究中达成主要终点：18 个月 PFS 66.7%（80%CI 57.5–74.4，p=0.0045），中位 PFS 25.1 个月；MARIPOSA 进一步显示其对比 osimertinib（EGFR T790M）带来 OS 延长（HR 0.75，P=0.005）。在 EGFR 敏感突变一线趋饱和的背景下，双抗+TKI 正争夺「更长的生存」。 ③ CTLA-4×PD-1 双抗：围手术期与一线「抢滩」。cadonilimab（CTLA-4×PD-1）围手术期化疗 pCR 28.9%、MPR 52.6%，不可切除 III 期同步放化疗后 1 年 PFS1 69.2%、ORR 85.4%；Opamtistomig（PD-L1×4-1BB）（LBL-024）一线联合化疗 ORR 65.0%（PD-L1≥1% 亚组 78.3%）；Rilvegostomig（PD-1×TIGIT）在 PD-L1≥50% 队列确认 ORR 61.8%、mPFS 16.7 个月、24 个月 OS 率 67.6%；JS207（PD-1×VEGF）新辅助 pCR 54.5%、MPR 72.7%。 ④ PD-1×CTLA-4×VEGF 三抗：把「双免疫 + 抗血管」装进一个分子。相比双抗，三抗致力于在一个分子上同时拮抗 CTLA-4（免疫启动）、PD-1（免疫效应）与 VEGF（血管微环境去抑）。本届 WCLC 2026 亮相的 HC010（PD-1×CTLA-4×VEGF）（宏成/倍特）公布了首次人体 Phase I：69 例可评估 ORR 14.5%、DCR 71%，其中免疫治疗难治性 NSCLC 亚组 ORR 25%、DCR 75%，最优剂量组（31 例）呈趋势更好；≥3 级 TRAE 24.1%，常见为皮疹 38.0%（G3 1.3%）、甲减 22.8%、AST/ALT 及贫血各 20.3%。同一靶点的 CS2009（PD-1×CTLA-4×VEGF）（基石）走得更远：已入组近 300 例、POC 落地，一线 PD-L1 高表达 ORR 81.3%、后线 IO 耐药 NSCLC ORR 30.8%，III 期 MRCT 计划 2026 年底启动。二、ADC 浪潮：靶点扩张 +「双抗 ADC」本届 ADC 的核心变化是：从广谱表达的「泛癌种靶点」（TROP2/HER2/HER3 等，靠适应症广取胜），走向肿瘤选择性更强的「精准靶点」（DLL3/SEZ6 等）与「双抗 ADC」，以拓宽治疗窗、降低靶向脱靶毒性，并加速向 SCLC、罕见病理类型渗透。 ① 双抗 ADC 登场。ALK202（EGFR×c-MET 双抗 ADC）在 EGFR 突变非鳞 NSCLC 中，高剂量组 ORR 42.9%、DCR 92.9%，3.2 mg/kg D1/D8 组 ORR 50%、DCR 100%——把双抗的「协同内吞」与 ADC 的「精准杀伤」结合。≥3 级 TRAE 65.8%，血液学毒性仍是主要约束。 ② TROP2 赛道：疗效分化，亚组深挖。sacituzumab tirumotecan（TROP2，sac-TMT）在高肿瘤负荷（≥3 转移灶）亚组显著获益：mOS 未达到 vs 化疗 15.7 个月（HR 0.49），18 个月 OS 率 63.4% vs 37.6%，ORR 61.7% vs 43.7%；在其他可操作基因组改变（AGA）人群 ORR 34.4%、中位 DOR 12.7 个月。 ③ 小细胞肺癌成 ADC 新蓝海。ABBV-706（SEZ6）治疗复发/难治 SCLC，既往数据 ORR 52%、mOS 11.3 个月，本次主要报告肺炎/ILD 4.2%；ifinatamab deruxtecan（B7-H3，I-DXd）在经治 ES-SCLC 疗效良好，ILD/肺炎 13.1%；YL201（B7-H3 ADC）联合 serplulimab（PD-1）一线 ES-SCLC 达 cORR 85.4%、mPFS 12.9 个月。tarlatamab（DLL3×CD3）在神经内分泌肿瘤取得 ORR 30%、CRS 80% 但均为 1–2 级。三、小分子精准治疗：罕见靶点与「耐药破局」并进在双抗与 ADC 之外，小分子依旧是驱动基因阳性肺癌的「底座」。本届在 EGFR、ALK/ROS1、KRAS、MET，以及四代 TKI/耐药后场景均密集发布数据，方向可归纳为四点：更优的生存、更广的罕见靶点、更强的大脑穿透、以及对抗耐药的「精准复合」。 ① EGFR-TKI：三代「内卷」，脑转移与联合成为胜负手。一线 befotertinib（EGFR） mPFS 22.0 个月 vs icotinib（EGFR） 13.8 个月（HR 0.52）；lazertinib（EGFR） mPFS 22.1 个月（Del-19 25.5 vs L858R 16.6 个月）；osimertinib（EGFR T790M）+ bevacizumab（VEGF-A） mPFS 19.8 vs 12.6 个月（HR 0.528）。脑转移是主场：furmonertinib（EGFR）颅内 ORR 85.4%、颅内 PFS 24.0 个月，联合 pemetrexed（化疗）后颅内 ORR 84%；osimertinib（EGFR T790M）+ savolitinib（MET）（MET 共突变，FLOWERS）mPFS 22.6 vs 单药 11.2 个月。 ② ALK/ROS1：生存竞速与「全程管理」。lorlatinib（ALK/ROS1） CROWN 7 年随访，mPFS 至今仍未达到 vs crizotinib（ALK/ROS1/c-MET） 9.1 个月，二次进展 PFS（PFS2）HR 0.43；taletrectinib（ROS1） TKI 初治 cORR 89.8%、mPFS 46.1 个月，经治 cORR 55.8%，覆盖既往耐药；alectinib（ALK）新辅助 MPR 55.8%、pCR 18.6%；ficonalkib（ALK）颅内 ORR 65.0% 且无神经毒性，向脑转移 ALK+ 人群延伸。 ③ KRAS：从 G12C 走向 G12D，「分子缓解」成新标尺。GFH375（KRAS G12D） ORR 54.7%、确认 ORR 49.1%、mPFS 8.1 个月，是 G12D 抑制剂中少见的具临床意义数据；adebrelimab（PD-L1）+ HS-10370（KRAS G12C）一线 ORR 87.0%、12 个月 PFS 率 80.2%；garsorasib（KRAS G12C）+ sitneprotafib（SHP2）以 ctDNA 动态分层，93.3% 基线阳性者于 C3D1 实现清除，未清除者 PFS 缩短至 4.3 个月——「分子缓解」正成为早期判断疗效的重要代理终点。 ④ MET 与罕见突变：精准「扩目录」。vebreltinib（c-MET）（MET 扩增）ORR 66.7–73.3%、mPFS 12.0–13.6 个月；osimertinib（EGFR T790M）+ vebreltinib（c-MET）（MET 共突变）mPFS 32.8 个月、确认 ORR 53.3%；dacomitinib（EGFR/HER2）治疗罕见 EGFR 突变 ORR 80%、mPFS 14.3 个月、mOS 44.2 个月。 ⑤ 耐药破局：四代 TKI 与 C797S。VRN110755（EGFR C797S）在 C797S 阳性亚组 ORR 87.5%、ctDNA C797S 清除率 83.3%；BH-30643（EGFR C797S，SOLARA）在 C797S 人群中 43% 达 RECIST 缓解、86% 肿瘤缩小，且无 MET/KRAS 共突变、未化疗者更优。C797S 这一 osimertinib（EGFR T790M）最常见的耐药机制，正成为下一代 EGFR-TKI 的攻坚重点。四、疗效之外：安全性管理成为胜负手双抗、ADC 这类「重武器」的 AE 管理越来越直接决定疗效能否兑现：telisotuzumab vedotin（c-MET，Teliso-V）的周围神经病变（PN）亚组提示 ≥2 级 PN 与更高累积剂量（31 vs 11 mg）和更长治疗（9 vs 2 个月）相关；ABBV-706（SEZ6）的间质性肺炎/ILD 发生率仅 4.2%、中位起病 96 天，多可恢复；ifinatamab deruxtecan（B7-H3）（I-DXd）的 ILD/肺炎 13.1%（≥3 级 4.4%），提示 B7-H3 类 ADC 需重点管理肺部毒性——把剂量-暴露关系与毒性谱做透，是从「能获批」走向「能长期用」的关键。五、关键数据速览（依据本届前瞻摘要）代表药物 / 方向关键数据看点 ivonescimab（PD-1×VEGF）三代TKI耐药后 mOS 16.8 vs 14.0 月，HR 0.76 EGFR耐药后首个OS获益双抗 RC148（PD-1×VEGF）鳞癌一线 ORR 90.0%；PD-L1阴性 93.3% 卡位PD-L1阴性人群 amivantamab（EGFR×c-MET）+ lazertinib（EGFR） AMIGO-1 18m-PFS 66.7%；mPFS 25.1 月双抗+TKI 挑战奥希替尼 Rilvegostomig（PD-1×TIGIT） PD-L1≥50% 确认ORR 61.8%；mPFS 16.7 月 PD-1×TIGIT 一线免疫 ALK202（EGFR×c-MET 双抗ADC） 3.2mg/kg 组 ORR 50%、DCR 100% 双抗+ADC 技术融合 sacituzumab tirumotecan（TROP2）高肿瘤负荷 mOS HR 0.49；ORR 61.7% 疗效亚组深挖 ABBV-706（SEZ6） R/R SCLC ORR 52%、mOS 11.3 月 SCLC 新靶点 ADC YL201（B7-H3 ADC）+ serplulimab（PD-1） ES-SCLC 一线 cORR 85.4%、mPFS 12.9 月小细胞肺癌一线组合 taletrectinib（ROS1） TKI初治 cORR 89.8%、mPFS 46.1 月 ROS1 全程管理 furmonertinib（EGFR）+ pemetrexed ORR 88%、CNS ORR 84% 脑转移颅内应答六、总结 ① 竞争格局：EGFR 敏感突变一线趋饱和，真正的「战场」在耐药后与围手术期。谁能带来 OS 获益（而非仅 PFS），谁才有资格进入标准治疗——ivonescimab（PD-1×VEGF）、amivantamab（EGFR×c-MET）+ lazertinib（EGFR）均瞄准这一点。 ② ADC 从「泛肿瘤靶点」走向「精准+双抗」，并向 SCLC/罕见病理类型渗透。 TROP2 渐显拥挤，DLL3、SEZ6、HER3、c-MET 等新靶点与双抗 ADC 将成为下一条差异化赛道。 ③ 「分子缓解」与「安全性深度」成为新的研究竞争力。 ctDNA 清除、毒性谱（ILD/PN/CRS）的精细管理，会越来越多地影响临床开发策略与同类竞争。 ④ 未满足需求仍在：脑转移颅内疗效、罕见驱动基因（ROS1/罕见 EGFR/KRAS 耐药）、以及小细胞肺癌的长期生存，仍是值得投入的方向。总体而言，WCLC 2026 传递的信号是：肺癌治疗正从「单药/单靶」走向「双抗 × ADC × 小分子的精准组合」，市场欢迎在特定人群、特定场景带来确定性生存获益与可控安全性的差异化资产。（说明：本文全部数据源自 WCLC 2026 大会前瞻摘要，仅作信息梳理与行业观察；数值以官方最终发布为准，不构成临床或投资建议。）

2026-08-21

·PRNewswire

AbbVie to Present New Data at WCLC 2026 Showcasing Innovation Across Lung Cancer Pipeline

Clinical data from AbbVie's ABBV-1480 (RC148) PD-1/VEGF bispecific antibody in the frontline non-small cell lung cancer (NSCLC) setting will be presented via an oral presentation Additionally, new data and updates from AbbVie's telisotuzumab adizutecan (Temab-A) and ABBV-706 programs across NSCLC and small cell lung cancer (SCLC) to be shared Research reflects AbbVie's strategy aimed at building a lung cancer pipeline spanning next-generation immunotherapies, targeted antibody-drug conjugates (ADCs) and the potential for novel combination approaches NORTH CHICAGO, Ill., Aug. 21, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced new data highlighting research programs across its lung cancer portfolio being presented at the 2026 World Conference on Lung Cancer (WCLC), including non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). The presentations span clinical, translational and real-world data across next-generation immunotherapies and targeted antibody-drug conjugates (ADCs), designed to generate insights into treatment burden, patient experience and biomarker identification that may help inform future research. "Our strategy in lung cancer is focused on building a complementary pipeline that brings together next-generation immunotherapies and targeted antibody-drug conjugates with the potential to address different aspects of tumor biology," said Daejin Abidoye, M.D., vice president and therapeutic area head of oncology, solid tumor and hematology at AbbVie. "Exploring the PD-1/VEGF approach represented by ABBV-1480 and the c-Met targeting by Temab-A are important elements of that strategy and may provide a foundation for potential novel combinations as we work to develop more tailored treatment approaches for people living with lung cancer." Advancing Novel Therapies Across Various Modalities in NSCLC Multiple presentations across AbbVie's NSCLC portfolio will showcase new studies and data analyses spanning multiple treatment modalities, highlighting first-line treatment approaches, patient experience and biomarker-informed research. ABBV-1480 (RC148): AbbVie, in partnership with RemeGen, will present Phase 1b data evaluating the investigational PD-1/VEGF bispecific antibody, ABBV-1480, in combination with platinum-based chemotherapy as a potential first-line treatment for advanced NSCLC. At the 10 mg/kg dose, identified as the recommended Phase 3 dose for further development in combination regimens in both squamous and non-squamous NSCLC, the primary endpoint of objective response rate (ORR) was 90.0% in squamous NSCLC (n=27/30) and 75.9% (n=22/29) in non-squamous NSCLC. The most common treatment-related adverse events (TRAEs) were a decrease in white blood cells, neutrophil, platelet counts and anemia. No grade ≥3 hemorrhages with the 10 mg combinations were observed. This overall manageable safety profile supports ongoing Phase 3 development for this novel investigational asset.1 Telisotuzumab adizutecan (Temab-A), an investigational c-Met-directed ADC with a topoisomerase 1 inhibitor (Top1i) payload: Building on encouraging preliminary activity2 observed in heavily pretreated patients, AbbVie initiated a Phase 1b/2 M24-536 study (NCT06772623). The study is evaluating a platinum-free combination of Temab-A and a PD-1 inhibitor, as a potential first-line treatment for advanced non-squamous NSCLC. The study includes analyses of c-Met and PD-L1 expression to identify the patients most likely to benefit from treatment.3 Temab-A is also being studied in epidermal growth factor receptor (EGFR)-mutated NSCLC as monotherapy or in combination with osimertinib (NCT07155187). Clinical Data Showcasing the Potential of ABBV-706 in SCLC ABBV-706 is an investigational SEZ6-targeted ADC with a Top1i payload, being evaluated in SCLC. Presentations at WCLC include research that further characterizes the program and the potential role of SEZ6 in SCLC. As previously reported, ABBV-706 demonstrated an ORR of 82% in patients with relapsed/refractory SCLC post platinum-based chemotherapy (n=17).4 New safety analyses from 240 patients who received ABBV-706 monotherapy showed generally manageable hematologic and gastrointestinal toxicities, with the most common gastrointestinal events, including nausea (35.8%), vomiting (17.5%) and diarrhea (10.8%), being largely low grade and most requiring no dose adjustments.5 Grade ≥3 treatment-related pneumonitis or interstitial lung disease was reported in 1.7% of patients receiving ABBV-706 monotherapy.6 Hematologic toxicities, including anemia, neutropenia and thrombocytopenia, were among the most common TRAEs.5 Serious TRAEs occurred in 12.5% of patients. ABBV-706 is being evaluated as monotherapy in a Phase 3 study (NCT07365241) and in combination with atezolizumab in the Phase 2 study (NCT07155174), in SCLC. Real-world research demonstrated that SEZ6 is broadly expressed in 91% of SCLC patients overall and in more than 96% of patients with brain or liver metastases. These findings further support SEZ6 as a potential therapeutic target in SCLC and other SEZ6-expressing tumors. 7 Additional details on key presentations are available below, and the full WCLC 2026 abstracts are available online. For information about AbbVie's clinical trial efforts in lung cancer, please visit clinicaltrials.gov. Telisotuzumab adizutecan (Temab-A) and ABBV-706 are investigational medicines and are not approved by any health authorities worldwide. The safety and efficacy of these investigational medicines are under evaluation as part of ongoing clinical studies. AbbVie holds exclusive rights from RemeGen to develop, manufacture, and commercialize ABBV-1480 outside of the Greater China territory. Emrelis™ (telisotuzumab vedotin-tllv) is an approved medicine being investigated for additional uses. Safety and efficacy have not been established for these unapproved additional uses. U.S. Prescribing Information for AbbVie Medicines Please see full Prescribing Information for EMRELIS™ (telisotuzumab vedotin-tllv). About AbbVie AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, neuroscience and oncology – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at . Follow @abbvie on LinkedIn, Facebook, Instagram, X and YouTube. About AbbVie in Oncology  AbbVie is committed to elevating standards of care and bringing transformative therapies to patients worldwide living with difficult-to-treat cancers. We are advancing a dynamic pipeline of investigational therapies across a range of cancer types in both blood cancers and solid tumors. We are focusing on creating targeted medicines that either impede the reproduction of cancer cells or enable their elimination. We achieve this through various, targeted treatment modalities and biology interventions, including small molecule therapeutics, antibody-drug conjugates (ADCs), immuno-oncology-based therapeutics, multispecific antibody and novel CAR-T platforms. Our dedicated and experienced team joins forces with innovative partners to accelerate the delivery of potential breakthrough medicines.  Today, our expansive oncology portfolio comprises approved and investigational treatments for a wide range of blood cancers and solid tumors. We are evaluating more than 35 investigational medicines in multiple clinical trials across some of the world's most widespread and debilitating cancers. As we work to have a remarkable impact on people's lives, we are committed to exploring solutions to help patients obtain access to our cancer medicines. For more information, please visit .  Forward-Looking Statements Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry, the impact of global macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes and tariffs, and other uncertainties and risks associated with global business operations. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2025 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents that AbbVie subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law. References: Zhang L, Zhao Y, Fan Y, et al. RC148 (ABBV-1480, PD-1/VEGF bispecific antibody) plus chemotherapy in first-line locally advanced or metastatic non-small cell lung cancer. Abstract OA14.01.03. presented at the World Conference on Lung Cancer, 2026. Seoul, Republic of Korea. De Miguel M, Yamamoto N, Raimbourg J, et al. ABBV-400, a c-Met protein-targeting antibody-drug conjugate (ADC), in patients with advanced EGFR wild-type non-squamous non-small cell lung cancer: results from a phase I study. Ann Oncol. 2024;35(Suppl):S805-S806. Abstract 1257MO. Horinouchi H, Cuppens K, Camidge DR, et al. Telisotuzumab adizutecan and PD-1 inhibitor in untreated advanced non-squamous non-small cell lung cancer: a phase 1b/2 study. Abstract P2.374. presented at the World Conference on Lung Cancer, 2026. Seoul, Republic of Korea. Byers LA, Cho BC, Cooper AJ, et al. ABBV-706 as monotherapy and in combination with budigalimab in patients with relapsed/refractory (R/R) small cell lung cancer (SCLC). J Clin Oncol 44, 8008-8008 (2026). Chiang AC, Byers LA, Cooper AJ, et al. Hematologic and Gastrointestinal Toxicity of ABBV-706 in Advanced Solid Tumors: Safety Profile from the First-in-Human Study. Abstract P3.316. presented at the World Conference on Lung Cancer, 2026. Seoul, Republic of Korea. Paz-Ares L, Chandana S, Chiang AC, et al. Pneumonitis/Interstitial Lung Disease in the First-in-Human ABBV-706 Study: Incidence, Management, and Risk Factors. E-Poster EP13.32. presented at the World Conference on Lung Cancer, 2026. Seoul, Republic of Korea. Jahchan N, Calip GS, Guadamuz JS, et al. SEZ6 is expressed across major clinical and demographic groups of SCLC patients: evidence from a US clinicogenomic database. Abstract P3.340. presented at the World Conference on Lung Cancer, 2026. Seoul, Republic of Korea. SOURCE AbbVie 21% more press release views with Request a Demo

临床结果临床1期抗体药物偶联物免疫疗法临床3期

2026-08-20

·北京医学感染与传染研究

自然医学 32卷 7-8期（2026年8月20日更新）

Nature Medicine Volume 32 Issue 7 自然医学 32卷 7期 https://www.nature.com/nm/volumes/32/issues/7 Editorial（社论） 1 Oncology must confront hidden side effects 肿瘤学必须正视隐匿不良反应 Nature Medicine volume 32（7）, page 2321 News（新闻） 2 Taming the inflamed heart 调控炎症性心脏病变 Charlotte Harrison Nature Medicine volume 32（7）, pages 2322-2323 News Feature（新闻专题） 3 When the real world becomes the trial 当现实世界成为临床试验场域 Marianne Guenot Nature Medicine volume 32（7）, pages 2324–2327 Correspondence（读者来信） 4 What Galen’s dissections reveal about tacit learning in modern medical education 盖伦解剖研究对现代医学教育中默会学习的启示 Andres PelavskiGabriele TorcolettiOrly Lewis Nature Medicine volume 32（7）, pages 2328–2329 5 What Utah’s clinical AI sandbox reveals about independent oversight 犹他州临床人工智能沙箱对独立监管机制的启示 Rahul GorijavoluNikhil JaiswalLeo Anthony Celi Nature Medicine volume 32（7）, pages 2330–2332 6 A case of artificial intelligence-enhanced diagnostics leading to heart transplantation 人工智能辅助诊断促成心脏移植一例 Heidi S. HartmanJoshua FinerPierre Elias Nature Medicine volume 32（7）, pages 2333–2334 7 Unintended consequences of legacy oversight in digital medicine 数字医学领域传统监管模式带来的非预期后果 Jochen K. LennerzDaniela AllendeAnne M. Stowman Nature Medicine volume 32（7）, pages 2335–2337 8 Incretin therapies, nutrition and food insecurity in the UK 英国肠促胰素治疗、营养状况与粮食不安全问题 Marie SpreckleyCara F. RuggieroAdrian Brown Nature Medicine volume 32（7）, pages 2338–2339 World View（全球观点） 9 Manageable toxicity is not a label — it is an oxymoron 可控制毒性并非标签，而是矛盾表述 From the patient’s perspective, toxicity is manageable only when it is met with empathy. 从患者视角而言，只有饱含人文关怀，不良反应才谈得上可控。 Laura Book Nature Medicine volume 32（7）, page 2340 10 Downplaying toxicities in cancer drug trials is not acceptable 肿瘤药物临床试验中淡化不良反应不可取 Bishal Gyawali Nature Medicine volume 32（7）, page 2341 Comment（述评） 11 Wearables as personal health custodians 可穿戴设备：个人健康守护者 Lei LuJosip Car Nature Medicine volume 32（7）, pages 2342–2345 12 Australia legislates against genetic discrimination in life insurance 澳大利亚立法禁止人寿保险领域的基因歧视 Jane Tiller Nature Medicine volume 32（7）, pages 2346–2348 13 A roadmap to competitive preclinical packages 具备竞争力的临床前研究方案构建路线图 Mustafa KhasrawMegan C. BenzJose R. Conejo-Garcia Nature Medicine volume 32（7）, pages 2349–2352 14 Brain Health for Economic Resilience: a data-driven framework for the brain-positive economic transition 保障大脑健康助力经济韧性：推动益脑经济转型的数据驱动框架 Harris A. EyreRym AyadiSimon Fischer-Baum Nature Medicine volume 32（7）, pages 2353–2355 News & Views（新闻与观点） 15 Long-term health risks of e-cigarettes after smoking cessation 戒烟后使用电子烟的长期健康风险 Mahdi SheikhPamela M. Ling Nature Medicine volume 32（7）, pages 2356–2357 16 CAR T cells take on precancers CAR-T细胞靶向癌前病变 Eric M. JurgensSham Mailankody Nature Medicine volume 32（7）, pages 2358–2359 17 Lassa fever countermeasures gather pace 拉沙热防控举措加速推进 Daniel Jenkin Nature Medicine volume 32（7）, pages 2360–2361 18 Shifting the goalposts in obesity drug development 肥胖药物研发目标的重新界定 W. Timothy Garvey Nature Medicine volume 32（7）, pages pages 2362–2363 Research Briefings（研究简报） 19 General-purpose chatbots outperform clinical AI tools on physicians’ real-world questions 通用对话机器人在医师现实临床问题上表现优于专用临床人工智能工具 Nature Medicine volume 32（7）, pages 2364–2365 20 An AI framework for multi-disease detection via retinal imaging 基于视网膜影像的多疾病筛查人工智能框架 Nature Medicine volume 32（7）, pages 2366–2367 Perspectives（前瞻观点） 21 Immune aging biomarkers for clinical trials 适用于临床试验的免疫衰老生物标志物 Andrea CiprianoJamie JusticeChiara M. S. Herzog Nature Medicine volume 32（7）, pages 2368–2382 Review Articles（综述） 22 Biological aging clocks in health and disease 健康与疾病状态下的生物学衰老时钟 Tony Wyss-CorayEric J. Topol Nature Medicine volume 32（7）, pages 2383–2394 Matters Arising（学术争鸣） 23 Limited evidence of AI superiority in seasonal influenza vaccine strain selection 尚无充分证据证明人工智能在季节性流感疫苗毒株筛选中具备优势 Simon P. J. de JongColin A. Russell Nature Medicine volume 32（7）, pages 2395–2397 24 Reply to: Limited evidence of AI superiority in seasonal influenza vaccine strain selection 对《尚无充分证据证明人工智能在季节性流感疫苗毒株筛选中具备优势》一文的回应 Wenxian ShiJeremy WohlwendRegina Barzilay Nature Medicine volume 32（7）, pages 2398–2400 Brief Communications（简讯） 25 Spatiotemporal diffusion of the 2024 Oropouche outbreak in Cuba 2024年古巴奥罗普切热暴发的时空传播特征 Rosario GravierMelissa M. PerezMaria G. Guzman Nature Medicine volume 32（7）, pages 2401–2404 26 General-purpose large language models outperform specialized clinical AI tools on medical benchmarks 通用大语言模型在医学基准测试中优于专用临床人工智能工具 Krithik VishwanathAnton AlyakinEric Karl Oermann Nature Medicine volume 32（7）, pages 2405–2409 Articles（论著） 27 Electronic cigarette use after smoking cessation and lung cancer risk 戒烟后使用电子烟与肺癌风险 Yeon Wook KimEung Joo ParkChoon-Taek Lee Nature Medicine volume 32（7）, pages 2410–2419 28 Ciltacabtagene autoleucel in high-risk smoldering multiple myeloma: the CAR-PRISM phase 2 trial Ciltacabtagene autoleucel治疗高危冒烟型（无症状）多发性骨髓瘤：CAR-PRISMⅡ期临床试验 Omar NadeemDavid M. Cordas dos SantosIrene M. Ghobrial Nature Medicine volume 32（7）, pages 2420–2429 29 Cibisatamab and FAP-4-1BBL in microsatellite-stable colorectal cancer: a phase 1b trial Cibisatamab联合FAP-4-1BBL治疗微卫星稳定型结直肠癌：Ⅰb期临床试验 Ignacio MeleroTamara TanosVictor Moreno Nature Medicine volume 32（7）, pages 2430–2439 30 Teclistamab-based induction treatment in transplant-eligible, newly diagnosed multiple myeloma: a phase 2 trial 基于Teclistamab的诱导方案治疗适合移植初诊多发性骨髓瘤：Ⅱ期临床试验 Marc S. RaabNiels WeinholdK. Martin Kortüm Nature Medicine volume 32（7）, pages 2440–2448 31 Anti-LAG-3 with or without anti-PD-1 in recurrent glioblastoma: a phase 1 trial 抗LAG-3单抗联合或不联合抗PD-1单抗治疗复发性胶质母细胞瘤：Ⅰ期临床试验 Michael LimXiaobu YeStuart A. Grossman Nature Medicine volume 32（7）, pages 2449–2460 32 Neoadjuvant stereotactic body radiation therapy with durvalumab and oleclumab in ER+HER2− breast cancer: a randomized phase 2 trial 立体定向体部放疗联合度伐利尤单抗与奥来鲁单抗新辅助治疗ER阳性HER2阴性乳腺癌：随机Ⅱ期临床试验 Alex De CaluwéIsabelle DesmoulinsLaurence Buisseret Nature Medicine volume 32（7）, pages 2461–2472 33 Post-adjuvant chemotherapy in ctDNA-positive patients with resected colorectal cancer: a randomized phase 3 trial ctDNA阳性结直肠癌术后辅助化疗：随机Ⅲ期临床试验 Hideaki BandoJun WatanabeTakeshi Kato Nature Medicine volume 32（7）, pages 2473–2480 34 Multi-antigen-targeting T cells in pediatric central nervous system tumors: a phase 1 trial 多抗原靶向T细胞治疗儿童中枢神经系统肿瘤：Ⅰ期临床试验 Stephanie GomezRachel A. DiCioccioEugene I. Hwang Nature Medicine volume 32（7）, pages 2481–2493 35 AI framework for multidisease detection via retinal imaging 基于视网膜影像的多疾病筛查人工智能框架 Xiayin ZhangQinyi LiHonghua Yu Nature Medicine volume 32（7）, pages 2494–2503 36 Long-term independent use of an intracortical brain–computer interface for speech and cursor control 皮层内脑机接口用于语音与光标控制的长期独立应用研究 Nicholas S. CardTyler Singer-ClarkDavid M. Brandman Nature Medicine volume 32（7）, pages 2504–2510 37 Adjuvanted inactivated rabies virus-vectored Lassa virus vaccine in healthy adults: a phase 1 trial 含佐剂灭活狂犬病毒载体拉沙病毒疫苗在健康成人中的Ⅰ期临床试验 Justin R. OrtizDrishya KurupMatthias J. Schnell Nature Medicine volume 32（7）, pages 2511–2521 38 Favipiravir for Lassa fever: an open-label, randomized controlled phase 2 trial 法匹拉韦治疗拉沙热：开放标签随机对照Ⅱ期临床试验 Cyril EramehKevin OkwaraekeMirjam Groger Nature Medicine volume 32（7）, pages 2522–2532 39 Bispecific 10E8.4/iMab broadly neutralizing antibody in people with or without HIV-1: a partially randomized phase 1 trial 双特异性广谱中和抗体10E8.4/iMab在HIV-1感染者与健康人群中的部分随机Ⅰ期临床试验 Deborah A. TheodoreBryan T. MayerMagdalena E. Sobieszczyk Nature Medicine volume 32（7）, pages 2533–2545 40 15-strain live biotherapeutic product or same donor fecal microbiota transplant for recurrent Clostridioides difficile infection: a randomized phase 1b trial 15菌株活体生物制剂与同源供体粪菌移植治疗复发性艰难梭菌感染：随机Ⅰb期临床试验 Lukas BethlehemLorenza BartuAri Grinspan Nature Medicine volume 32（7）, pages 2546–2555 41 Innate immune responsiveness predicts enhanced cellular immunity and symptomatic disease after controlled human influenza infection 固有免疫应答水平可预测人工流感感染后细胞免疫增强与临床发病情况 Loukas PapargyrisJiayun XuChristopher Chiu Nature Medicine volume 32（7）, pages 2556–2569 42 Efficacy and target engagement of dopamine agonist pramipexole for anhedonic depression: a randomized placebo-controlled trial 多巴胺激动剂普拉克索治疗快感缺失型抑郁症的疗效与靶点作用验证：随机安慰剂对照试验 Filip VentorpMarie AspDaniel Lindqvist Nature Medicine volume 32（7）, pages 2570–2578 43 Spinal cord stimulation for upper limb motor function in people with chronic post-stroke hemiparesis: a feasibility trial 脊髓电刺激改善慢性卒中后偏瘫患者上肢运动功能：可行性临床试验 Roberto M. de FreitasShovan BhatiaMarco Capogrosso Nature Medicine volume 32（7）, pages 2579–2590 44 A neuroprosthesis for restoring hand movement and sensation in a person with complete tetraplegia 神经假体用于重建完全四肢瘫痪患者手部运动与感觉功能 Santosh ChandrasekaranSarah K. WandeltChad E. Bouton Nature Medicine volume 32（7）, pages pages2591–2601 45 Dual-target gene therapy in Parkinson’s disease: a multicenter phase 1 trial 双靶点基因疗法治疗帕金森病：多中心Ⅰ期临床试验 Mengyue NiuJifeng GuoJun Liu Nature Medicine volume 32（7）, pages 2602–2609 46 Abatacept versus hydroxychloroquine for prevention of rheumatoid arthritis in individuals with palindromic rheumatism: a randomized open-label trial 阿巴西普对比羟氯喹预防复发性风湿症进展为类风湿关节炎：随机开放标签试验 Raimon SanmartiCarolina Pérez-GarcíaIsabel Haro Nature Medicine volume 32（7）, pages 2610–2618 47 Oligonucleotide–siRNA conjugate for SOD1 amyotrophic lateral sclerosis: a phase 1 trial 寡核苷酸-siRNA偶联药物治疗SOD1相关肌萎缩侧索硬化：Ⅰ期临床试验 Weiqi ChenLingling JiangYilong Wang Nature Medicine volume 32（7）, pages 2619–2628 48 Multinational validation of the PREVENT and SCORE2心血管风险方程 across 6.4 million individuals 基于640万人群的多国验证：PREVENT与SCORE2心血管风险预测方程 Brendon L. NeuenRupert W. MajorVilmantas Giedraitis Nature Medicine volume 32（7）, pages 2629–2638 49 Cliramitug for depletion of cardiac amyloid transthyretin: long-term follow-up of the NI006-101 trial Cliramitug清除心脏转甲状腺素蛋白淀粉样物质：NI006-101试验长期随访结果 Peter C. KahrFabian aus dem SiepenPeter van der Meer Nature Medicine volume 32（7）, pages 2639–2646 50 Low-dose digoxin in patients with heart failure with reduced or mildly reduced ejection fraction: a randomized controlled trial 小剂量地高辛治疗射血分数降低或轻度降低心力衰竭：随机对照试验 D. J. van VeldhuisenM. RienstraP. van der Meer Nature Medicine volume 32（7）, pages 2647–2653 51 The microRNA inhibitor CDR132L in patients with reduced left ventricular ejection fraction after myocardial infarction: a randomized phase 2 trial 微小RNA抑制剂CDR132L治疗心肌梗死后左室射血分数降低患者：随机Ⅱ期临床试验 Johann BauersachsScott D. SolomonThomas Thum Nature Medicine volume 32（7）, pages 2654–2661 52 Semaglutide versus placebo in individuals with poor weight loss after bariatric surgery: a double-blinded, randomized, placebo-controlled trial 司美格鲁肽对比安慰剂治疗减重手术术后减重不佳人群：双盲随机安慰剂对照试验 Chloe StanleyRitwika MallikJanine Makaronidis Nature Medicine volume 32（7）, pages 2662–2672 53 Apitegromab for lean mass preservation during tirzepatide-induced weight loss: a randomized, double-blind, placebo-controlled phase 2 trial Apitegromab用于替尔泊肽减重过程中维持瘦体重：随机双盲安慰剂对照Ⅱ期临床试验 Richard E. PratleyDouglas Scott DenhamJing L. Marantz Nature Medicine volume 32（7）, pages 2673–2678 54 Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial Orforglipron用于维持减重效果：双盲随机Ⅲb期ATTAIN-MAINTAIN试验 Louis J. AronneDeborah B. HornNeena Xavier Nature Medicine volume 32（7）, pages 2679–2687 Amendments & Corrections（勘误与更正） 55 Author Correction: Teclistamab-based induction treatment in transplant-eligible, newly diagnosed multiple myeloma: a phase 2 trial 作者更正：基于Teclistamab的诱导方案治疗适合移植初诊多发性骨髓瘤：Ⅱ期临床试验 Marc S. RaabNiels WeinholdK. Martin Kortüm Nature Medicine volume 32（7）, page 2688 56 Author Correction: Digital AVATAR therapy for distressing voices in psychosis: the phase 2/3 AVATAR2 trial 作者更正：数字虚拟化身疗法治疗精神病幻听症状：Ⅱ/Ⅲ期AVATAR2临床试验 Philippa A. GaretyClementine J. EdwardsThomas Ward Nature Medicine volume 32（7）, page 2689 57 Author Correction: Global burden of amphetamine, cannabis, cocaine and opioid use in 204 countries, 1990–2023: a Global Burden of Disease Study 作者更正：1990–2023年204个国家苯丙胺、大麻、可卡因与阿片类物质使用的全球疾病负担研究 Jiseung KangHyeon Jin KimDong Keon Yon Nature Medicine volume 32（7）, page 2690 58 Retraction Note: Time-of-day immunochemotherapy in non-small cell lung cancer: a randomized phase 3 trial 撤稿声明：时辰免疫化疗治疗非小细胞肺癌：随机Ⅲ期临床试验 Zhe HuangLiang ZengYongchang Zhang Nature Medicine volume 32（7）, page 2691 Nature Medicine Volume 32 Issue 8 自然医学 32卷 8期 https://www.nature.com/nm/volumes/32/issues/8 Editorial（社论） 1 Anti‑aging interventions need less hype and more clinical evidence 抗衰老干预：少一些炒作，多一些临床证据 Editorial Nature Medicine volume 32（8）, page 2693 News（新闻） 2 A turning point for gene editing in severe blood disorders 基因编辑治疗重症血液疾病迎来转折点 Carrie Arnold Nature Medicine volume 32（8）, pages 2694-2696 News Feature（新闻特写） 3 Sleep as therapy 睡眠疗法 Carrie Arnold Nature Medicine volume 32（8）, pages 2697–2700 Correspondence（通信） 4 Genetic–exposome interactions and aging clocks in dementia: the ReDLat2 initiative 遗传‑暴露组相互作用与痴呆衰老时钟：ReDLat2研究计划 Agustin IbáñezJennifer S. YokoyamaBruce L. Miller Nature Medicine volume 32（8）, pages 2701–2703 5 Bundibugyo Ebola without vaccines or therapeutics: why public health fundamentals matter more than border closures 无疫苗与治疗药物情况下的本迪布焦埃博拉疫情：公共卫生基础措施比边境封锁更为重要 Ngashi NgongoMosoka Papa FallahJean Kaseya Nature Medicine volume 32（8）, pages 2704–2705 6 Fertilizer scarcity as a failure of global health governance 肥料短缺：全球卫生治理的一项失败 Alaha NasariAmina NasariJessica Fanzo Nature Medicine volume 32（8）, pages 2706–2707 7 Mapping the human chemical exposome for public health 面向公共卫生的人类化学暴露组图谱绘制 Arthur DavidSarah LennonMichel Samson Nature Medicine volume 32（8）, pages 2708–2710 World View（全球视野） 8 When caution becomes harm 当谨慎变为伤害 Simone N. Vigod Nature Medicine volume 32（8）, page 2711 Comment（述评） 9 Enabling secure discovery in trusted research environments with improved tooling 依托优化工具在可信研究环境中实现安全数据挖掘 Vincent J. StraubMelinda C. Mills Nature Medicine volume 32（8）, pages 2712–2715 10 Reinventing biotech systems for patient impact 重塑生物技术体系，惠及患者 Kushal T. KadakiaYashodhara DashAnaeze C. Offodile II Nature Medicine volume 32（8）, pages 2716–2719 11 Why large‑scale randomized trials of live‑attenuated shingles vaccination for dementia prevention are urgently needed 亟需开展减毒活带状疱疹疫苗预防痴呆的大规模随机对照试验 Pascal Geldsetzer Nature Medicine volume 32（8）, pages 2720–2723 12 Inspiring, shaping and sustaining an African research & development agenda 推动、构建并维系非洲研发议程 Mosoka P. FallahMisaki WayengeraJean Kaseya Nature Medicine volume 32（8）, pages 2724–2726 13 Data rights are the missing pillar for modernizing consent in medicine 数据权利：医学知情同意现代化的缺失支柱 Nada S. Salem Nature Medicine volume 32（8）, pages 2727–2728 Q&A（问答） 14 Reinventing health communication for the digital era 数字时代下重塑健康传播 Natalie Healey Collection: Nature Medicine Commission on Quality Health Information for All Nature Medicine volume 32（8）, pages 2729–2731 News & Views（新闻与观点） 15 Adaptive brain stimulation 2.0 for Parkinsonian gait 用于帕金森病步态障碍的第二代自适应脑刺激 Arjun BalachandarAlfonso Fasano Nature Medicine volume 32（8）, pages 2732–2734 16 A second chance for gene therapy to restore natural hearing 基因治疗重获契机，助力恢复天然听力 Nicola Strenzke Nature Medicine volume 32（8）, pages 2735–2737 17 From RAS inhibitor resistance to rational combination strategies 从RAS抑制剂耐药到合理联合治疗策略 Paula LynchTeresa MacarullaGrainne M. O’Kane Collection: Cancer at Nature Portfolio Nature Medicine volume 32（8）, pages 2738–2740 18 Deciphering the role of histidine in cancer 解析组氨酸在肿瘤中的作用 Feyza CansizAmanda N. PopeAlpaslan Tasdogan Nature Medicine volume 32（8）, pages 2741–2742 Research Briefings（研究简报） 19 Learning from routine health system data builds better neuroimaging AI models 基于常规卫生系统数据训练构建更优神经影像人工智能模型 Research Briefing Nature Medicine volume 32（8）, pages 2743–2744 20 Early detection of Alzheimer’s disease with circular RNA from blood 基于血液环状RNA实现阿尔茨海默病早期检测 Nature Medicine volume 32（8）, pages 2745–2746 21 Non‑invasive tests for the evaluation of liver fibrosis in MASLD 代谢相关脂肪性肝病肝纤维化的无创评估检测 Nature Medicine volume 32（8）, pages 2747–2748 22 Multi‑omics maps human–pig interactions in extracorporeal liver cross‑circulation 多组学解析体外肝交叉循环中人‑猪相互作用 Nature Medicine volume 32（8）, pages 2749–2750 23 Biological aging might help to explain the rising risk of early‑onset cancer 生物衰老或可解释早发性肿瘤风险升高现象 Nature Medicine volume 32（8）, pages 2751–2752 24 Delivering the benefits of genomic data reanalysis for diagnosis equitably and at scale 公平、规模化发挥基因组数据再分析的诊断价值 Nature Medicine volume 32（8）, pages 2753–2754 25 Why high scores do not mean application readiness for health AI 为何高分不等于健康人工智能具备实际应用就绪度 Nature Medicine volume 32（8）, pages 2755–2756 Perspectives（观点） 26 Type 2 diabetes prevention across the life course 全生命周期的2型糖尿病预防 Yiying WangJennifer L. SargentAndreas L. Birkenfeld Nature Medicine volume 32（8）, pages 2757–2773 27 The next generation of antibody–drug conjugates 新一代抗体‑药物偶联物 F. MoseleA. PeltierF. André Collection: Cancer at Nature Portfolio Nature Medicine volume 32（8）, pages 2774–2785 Brief Communications（简讯） 28 Clinical profile and genomic characterization of the 2026 Bundibugyo virus index case in Uganda 乌干达2026年本迪布焦病毒首发病例的临床特征与基因组分析 Andrew NsawotebbaIsaac SsewanyanaDiana Atwine Nature Medicine volume 32（8）, pages 2786–2789 Articles（论著） 29 Immersive virtual reality with synchronous neurostimulation for upper‑limb recovery after stroke: a randomized feasibility trial 沉浸式虚拟现实联合同步神经刺激用于脑卒中后上肢功能恢复：一项随机可行性试验 Giuseppe Valerio AurucciOlivera DjordjevicStanisa Raspopovic Nature Medicine volume 32（8）, pages 2790–2802 30 Adaptive deep brain stimulation for dynamic gait control in Parkinson’s disease: a randomized feasibility trial 自适应深部脑刺激用于帕金森病动态步态调控：一项随机可行性试验 Kenneth H. LouieJannine P. BalakidDoris D. Wang Nature Medicine volume 32（8）, pages 2803–2814 31 Activity‑dependent adaptive deep brain stimulation improves gait in Parkinson’s disease 活动依赖性自适应深部脑刺激改善帕金森病患者步态 Stefano ScafaValeria de SetaEduardo M. Moraud Nature Medicine volume 32（8）, pages 2815–2830 32 Health system learning enables generalist neuroimaging models 基于卫生系统数据学习构建通用型神经影像模型 Akhil KondepudiAkshay RaoTodd Hollon Nature Medicine volume 32（8）, pages 2831–2837 33 Individualized antisense oligonucleotides for SCN2A‑related developmental epileptic encephalopathy 针对SCN2A相关发育性癫痫性脑病的个体化反义寡核苷酸治疗 Olivia Kim‑McManusLaurence MignonElizabeth Berry‑Kravis Nature Medicine volume 32（8）, pages 2838–2845 34 Re‑administration of AAV‑mediated gene therapy for OTOF‑related deafness: a single‑arm trial OTOF相关耳聋腺相关病毒介导基因治疗的再次给药：一项单臂临床试验 Xintai FanLonglong ZhangYilai Shu Nature Medicine volume 32（8）, pages 2846–2856 35 Blood‑based circular RNAs for early diagnosis of Alzheimer’s disease 基于血液环状RNA的阿尔茨海默病早期诊断 Bridget PhillipsJessie SanfordCarlos Cruchaga Nature Medicine volume 32（8）, pages 2857–2864 36 Acquired resistance to the RAS(ON) multi‑selective inhibitor daraxonrasib guides rational combination therapy strategies in pancreatic cancer RAS(ON)高选择性抑制剂daraxonrasib获得性耐药指导胰腺癌合理联合治疗策略 Ida AronchikSumit KarMallika Singh Collection: Cancer at Nature Portfolio Nature Medicine volume 32（8）, pages 2865–2877 37 MAGE‑A4/MAGE‑A8‑targeted TCR‑based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trial 靶向MAGE‑A4/MAGE‑A8的TCR双特异性T细胞衔接分子治疗复发/难治性实体瘤：Ⅰ期临床试验 Martin WermkeSebastian OchsenreitherCarsten Reinhardt Nature Medicine volume 32（8）, pages 2878–2887 38 Savolitinib in MET‑amplified gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial 赛沃替尼治疗MET扩增胃癌或胃食管结合部腺癌：Ⅱ期临床试验 Zhi PengTianshu LiuZhongxian Zheng Nature Medicine volume 32（8）, pages 2888–2897 39 SEZ6‑targeting antibody−drug conjugate ABBV‑706 in advanced small cell lung cancer and solid tumors: a phase 1 trial 靶向SEZ6抗体‑药物偶联物ABBV‑706治疗晚期小细胞肺癌及其他实体瘤：Ⅰ期临床试验 Lauren Averett ByersByoung Chul ChoSreenivasa Chandana Nature Medicine volume 32（8）, pages 2898–2908 40 FcRH5×CD3 bispecific antibody cevostamab in relapsed or refractory multiple myeloma: a phase 1 trial FcRH5×CD3双特异性抗体ce vostamab治疗复发难治多发性骨髓瘤：Ⅰ期临床试验 Adam D. CohenJoshua RichterAmrita Krishnan Nature Medicine volume 32（8）, pages 2909–2917 41 Metabolic determinants of cancer immunotherapy outcomes identified by plasma profiling 基于血浆谱分析筛选肿瘤免疫治疗疗效的代谢决定因素 Déborah SuissaMarine FidelleLaurence Zitvogel Nature Medicine volume 32（8）, pages 2918–2932 42 Polypill for heart failure with reduced ejection fraction: the POLY‑HF randomized trial 射血分数降低心力衰竭复方制剂：POLY‑HF随机临床试验 Ambarish PandeyNeil KeshvaniThomas J. Wang Nature Medicine volume 32（8）, pages 2933–2940 43 Oral small molecule GLP‑1 receptor agonist aleniglipron in people with overweight or obesity: a randomized, double‑blind, placebo‑controlled phase 2b trial 口服小分子GLP‑1受体激动剂aleniglipron治疗超重/肥胖人群：随机双盲安慰剂对照Ⅱb期临床试验 Julio RosenstockIldiko LingvayBlai Coll Nature Medicine volume 32（8）, pages 2941–2947 44 Survodutide in adults with obesity and metabolic dysfunction‑associated steatotic liver disease: SYNCHRONIZE‑MASLD, a randomized, double‑blind, placebo‑controlled phase 3 trial Survodutide治疗合并代谢相关脂肪性肝病的肥胖成人：SYNCHRONIZE‑MASLD随机双盲安慰剂对照Ⅲ期临床试验 Lee M. KaplanElena StartsevaPaul Hellstern Nature Medicine volume 32（8）, pages 2948–2958 45 Prospective validation of imaging and serum diagnostic biomarkers of steatohepatitis and fibrosis in MASLD: the LITMUS Imaging Study 代谢相关脂肪性肝炎及肝纤维化影像与血清诊断生物标志物的前瞻性验证：LITMUS影像研究 Michael PavlidesYasaman ValiQuentin M. Anstee Nature Medicine volume 32（8）, pages 2959–2969 46 Longitudinal multiomics profiling of extracorporeal cross‑circulation with pig liver xenografts in human decedents 人逝者猪肝异种移植体外交叉循环的纵向多组学分析 Qian GuoChan WangBrendan J. Keating Nature Medicine volume 32（8）, pages 2970–2982 47 Biological aging and generational shifts in early‑onset cancer risk 生物衰老与早发性肿瘤风险的代际变迁 Ruiyi TianXiaoyu ZongYin Cao Nature Medicine volume 32（8）, pages 2983–2990 48 Automated reanalysis of genomic data for rare disease diagnostics at scale 面向大规模罕见病诊断的基因组数据自动化再分析 Matthew J. WellandK. D. AhlquistZornitza Stark Nature Medicine volume 32（8）, pages 2991–2999 49 Divergent impacts of explainable AI for dermatological diagnosis on clinicians versus lay people 可解释人工智能皮肤病诊断对临床医师与普通人群的差异化影响 Xuhai ‘Orson’ XuHaoyu HuMarzyeh Ghassemi Nature Medicine volume 32（8）, pages 3000–3009 50 Generalizable AI predicts immunotherapy outcomes across cancers and treatments 泛化人工智能跨肿瘤类型与治疗方案预测免疫治疗疗效 Wanxiang ShenIntae MoonMarinka Zitnik Nature Medicine volume 32（8）, pages 3010–3022 51 Evaluating the robustness and readiness of large frontier models in health AI applications 健康人工智能应用中大前沿模型的稳健性与就绪度评估 Yu GuJingjing FuPaul Vozila Nature Medicine volume 32（8）, pages 3023–3031 52 Generative AI‑enabled clinical decision support system in primary care: a pragmatic, cluster‑randomized trial 基层医疗机构生成式人工智能临床决策支持系统：一项实用整群随机试验 Ambrose AgweyuPaul MwanikiBilal A. Mateen Nature Medicine volume 32（8）, pages 3032–3039 53 Integrated care pathway in individuals with Long COVID: STIMULATE‑ICP, a cluster‑randomized, phase 3 trial 长新冠患者综合护理路径：STIMULATE‑ICP整群随机Ⅲ期临床试验 Amitava BanerjeeGordon PrescottYi Mu Nature Medicine volume 32（8）, pages 3040–3047 54 Maternal 6‑valent group B Streptococcus vaccine in non‑pregnant and pregnant females: a randomized phase 1/2 trial B族链球菌六价母体疫苗在非妊娠及妊娠女性中的随机Ⅰ/Ⅱ期临床试验 Shabir A. MadhiHasra SnaggsAlejandra Gurtman Nature Medicine volume 32（8）, pages 3048–3059 55 The genetic architecture of fibromyalgia across 2.5 million individuals 基于250万人群的纤维肌痛遗传结构研究 Isabel KerrebijnGyda BjornsdottirMichael Wainberg Nature Medicine volume 32（8）, pages 3060–3070 56 Povorcitinib for hidradenitis suppurativa: the randomized, double‑blind, placebo‑controlled STOP‑HS1 and STOP‑HS2 phase 3 trials Povorcitinib治疗化脓性汗腺炎：随机双盲安慰剂对照STOP‑HS1、STOP‑HS2两项Ⅲ期临床试验 Martina L. PorterAntonio MartorellChristos C. Zouboulis Nature Medicine volume 32（8）, pages 3071–3081 Analysis（分析） 57 A meta‑analysis of the long‑term effects of antihypertensive therapy on the risk of major cardiovascular disease across 51 randomized trials 纳入51项随机试验的降压治疗对主要心血管病风险长期影响的荟萃分析 Qianqian YangZeinab BidelKazem Rahimi Nature Medicine volume 32（8）, pages 3082–3092 Amendments & Corrections（修订与勘误） 58 Author Correction: SEZ6‑targeting antibody−drug conjugate ABBV‑706 in advanced small cell lung cancer and solid tumors: a phase 1 trial 作者勘误：靶向SEZ6抗体‑药物偶联物ABBV‑706治疗晚期小细胞肺癌及其他实体瘤：Ⅰ期临床试验 Lauren Averett ByersByoung Chul ChoSreenivasa Chandana Nature Medicine volume 32（8）, page 3093 59 Author Correction: MAGE‑A4/MAGE‑A8‑targeted TCR‑based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trial 作者勘误：靶向MAGE‑A4/MAGE‑A8的TCR双特异性T细胞衔接分子治疗复发/难治性实体瘤：Ⅰ期临床试验 Martin WermkeSebastian OchsenreitherCarsten Reinhardt Nature Medicine volume 32（8）, page 3094 60 Publisher Correction: Oral small molecule GLP‑1 receptor agonist aleniglipron in people with overweight or obesity: a randomized, double‑blind, placebo‑controlled phase 2b trial 出版方勘误：口服小分子GLP‑1受体激动剂aleniglipron治疗超重/肥胖人群：随机双盲安慰剂对照Ⅱb期临床试验 Julio RosenstockIldiko LingvayBlai Coll Nature Medicine volume 32（8）, page 3095

临床研究细胞疗法免疫疗法基因疗法

100 项与 ABBV-706 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
小细胞肺癌	临床3期	中国	AbbVie, Inc.	2026-08-19
小细胞肺癌	临床3期	比利时	AbbVie, Inc.	2026-08-19
小细胞肺癌	临床3期	巴西	AbbVie, Inc.	2026-08-19
小细胞肺癌	临床3期	意大利	AbbVie, Inc.	2026-08-19
复发性小细胞肺癌	临床3期	美国	AbbVie, Inc.	2026-07-02
复发性小细胞肺癌	临床3期	日本	AbbVie, Inc.	2026-07-02
复发性小细胞肺癌	临床3期	奥地利	AbbVie, Inc.	2026-07-02
复发性小细胞肺癌	临床3期	法国	AbbVie, Inc.	2026-07-02
复发性小细胞肺癌	临床3期	德国	AbbVie, Inc.	2026-07-02
复发性小细胞肺癌	临床3期	希腊	AbbVie, Inc.	2026-07-02

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05599984 (ASCO2026)	临床1期	复发性小细胞肺癌	124	ABBV-706 monotherapy	簾廠廠鬱衊構觸選簾醖(廠鹽顧鬱選鬱簾窪鏇壓) = 餘構積遞鑰簾築繭衊製鹽淵願製壓鬱鑰蓋繭淵 (獵遞範繭範構憲餘膚壓 ) 更多	积极	2026-05-29
NCT05599984 (ASCO2026)	临床1期	复发性小细胞肺癌	124	ABBV-706 1.8 mg/kg monotherapy	憲鹽餘繭鏇衊鬱窪廠膚(廠顧網網顧製廠餘顧鏇) = 顧餘襯艱鑰鑰醖鏇網鏇構艱顧窪夢網積願鏇衊 (遞淵鑰廠齋蓋構顧遞糧 ) 更多	积极	2026-05-29
NCT07155174 (SEZanne, ASCO2026 \| ESMO_ELCC2026)	临床2期	广泛期小细胞肺癌一线	180	ABBV-706 + atezo	構鹽廠鹽鹹衊築醖醖製(製獵膚壓遞餘繭襯觸夢) = 夢鬱積鏇範襯壓齋鑰壓願鹹構鑰鏇衊鑰網鏇願 (齋積鏇夢鑰網艱製餘觸 )	积极	2026-05-29
NCT05599984 (ESMO2025)	临床1期	复发性小细胞肺癌 seizure-related homolog protein 6 (SEZ6)	60	ABBV-706 1.8 mg/kg	壓繭繭製淵襯觸繭觸顧(窪鬱鑰鏇衊鹹鹽鬱獵壓) = 醖糧網範壓糧蓋淵淵窪鬱艱夢顧壓觸醖範觸積 (築鹹艱壓簾窪網襯艱鹽 ) 更多	积极	2025-10-17
NCT05599984 (ESMO2025)	临床1期	复发性小细胞肺癌 seizure-related homolog protein 6 (SEZ6)	60	ABBV-706 2.5 mg/kg	壓繭繭製淵襯觸繭觸顧(窪鬱鑰鏇衊鹹鹽鬱獵壓) = 憲鏇獵衊製膚鑰鹹願繭鬱艱夢顧壓觸醖範觸積 (築鹹艱壓簾窪網襯艱鹽 ) 更多	积极	2025-10-17
NCT05599984 (WCLC2025 \| NEWS) 人工标引	临床1期	广泛期小细胞肺癌	80	ABBV-706 1.8 mg/kg Q3WABBV-706 1.8 mg/kg Q3W	膚鬱襯鏇窪膚遞窪觸獵(繭憲醖顧鏇願繭鑰窪鏇) = 夢齋鑰獵繭醖觸襯膚鹽鹽夢簾鹽選壓衊網積齋 (襯簾遞夢窪遞艱鹽艱積 ) 更多	积极	2025-09-07
NCT05599984 (WCLC2025 \| NEWS) 人工标引	临床1期	广泛期小细胞肺癌	80	ABBV-706 2.5 mg/kg Q3WABBV-706 2.5 mg/kg Q3W	膚鬱襯鏇窪膚遞窪觸獵(繭憲醖顧鏇願繭鑰窪鏇) = 鹽蓋獵製選醖鹹衊築製鹽夢簾鹽選壓衊網積齋 (襯簾遞夢窪遞艱鹽艱積 ) 更多	积极	2025-09-07
NCT05599984 (ABBV-706, ASCO2025)	临床1期	神经内分泌肿瘤 SEZ6 expression	191	ABBV-706	艱築顧鑰遞齋壓糧齋醖(繭顧鏇簾衊遞鑰夢糧膚) = 夢壓蓋繭壓廠觸醖齋鏇構獵獵鏇繭選積衊鑰願 (願簾網構衊衊齋廠艱壓 ) 更多	积极	2025-05-30
NCT05599984 (phase 1 study of ABBV-706, ASCO2025)	临床1期	神经内分泌癌 SEZ6 expression \| ctDNA methylation profiles	64	ABBV-706	餘製網網網壓窪鏇憲膚(齋醖構衊衊範餘淵積鑰) = 餘範壓淵艱膚鑰鑰糧鑰蓋憲構製齋積壓淵鹹願 (鹽製積選壓鏇膚壓顧糧 )	积极	2025-05-30
NCT05599984 (ASCO2024)	临床1期	晚期恶性实体瘤 SEZ6 expression	49	ABBV-706	蓋鹽蓋鹹淵齋積顧範獵(範襯餘願壓餘餘餘觸獵) = 選衊壓襯觸顧鬱艱窪繭積選願蓋膚壓製繭鹹糧 (鏇廠簾顧襯憲構製醖醖 ) 更多	积极	2024-05-24